Skip to main content
Epocrates Online
Contact us
Explore features
Reach clinicians
Buy now
By
vgreene
, 10 January, 2019
No established ASCVD or CKD
By
vgreene
, 10 January, 2019
Cost is a major issue (low hypoglycemia/wt gain risk)
By
vgreene
, 10 January, 2019
Compelling need to minimize wt gain/promote wt loss
By
vgreene
, 10 January, 2019
Compelling need to minimize hypoglycemia
By
vgreene
, 10 January, 2019
Established ASCVD or CKD
By
vgreene
, 10 January, 2019
HF or CKD predominates
By
vgreene
, 10 January, 2019
ASCVD predominates
By
vgreene
, 10 January, 2019
Tx-experienced, but not at HBA1c target
By
vgreene
, 10 January, 2019
Newly diagnosed (treatment naive), HBA1c above target
By
vgreene
, 10 January, 2019
Diabetes already diagnosed, nonpregnant
Pagination
First page
Previous page
…
Page
2525
Page
2526
Page
2527
Page
2528
Current page
2529
Page
2530
Page
2531
Page
2532
Page
2533
…
Next page
Last page
About Us
Company Overview
Media Relations
Contact
Editorial Policy
Editorial Process
Third-Party Sponsorship Policy
athenahealth
Products
Core Products
Mobile CME
Product Licenses
Business Solutions
Pharma
Market Research
Institutions
Support
Support Center
Install
My Account
Stay Connected
Facebook
Twitter
YouTube